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I and coproporphyrinogen I are produced non-enzymatically and are not 
utilised biologically. 
Table 1.1 Names and side-chain substituents of porphyrins. A : -CH2COOH; 
E : -CH2CH3; M : -CH3; P : -CH2CH2COOH; V : -CH=CH2 
Substituent on positions 1-8 
PORPHYRIN 1 2 3 4 5 6 7 8 
Uroporphyrin-I A P A P A P A P 
Uroporphyrin-III A P A P A P P A 
Heptacarboxylic porphyrin A P A P A P P M 
He ptaca rboxyl ic porphyri n M P A P A P P M 
Pentacarboxylic porphyrin M P M P A P P M 
Coproporphyrin.1 M P M P M P M P 
Coproporphyrin-III M P M P M P P M 
Isocoporphyrin-III M E A P M P P M 
Harderoporphyrin-IX M V M P M P P M 
P rotoporphyri n-IX M V M V M P P M 
Deuteroporphyri n-IX M H M H M P P M 
Mesoporphyri n-IX M E M E M P P M 
Figure 1.1 The tetrapyrrole structure of porphyrins showing the four pyrrole rings joined 
by methene bridges (indicated in red). 
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Disorder Inheritance Clinical Effects 
ALADP ALA AR AA 
AlP PBG deaminase AD AA 
CEP Im!llQmlh\lrirlMI~n III syntlla!~ AR PS 
PCT AD (however, 800.40 of cases am PS 
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1A>G M1V France (Whatley et aI. 1999) 
1A>C M1l France (Whatley at at 1999) 
1A:>T Mil Lebanon (Frank et al. 1999) 
2T>C MiT lraland I Poland (Frank et at 1999) 
3G>C M11 France (Whatley at al. 1999) 
3G>A Mil Sweden (Wiman et al. 2003) 
31G>A G11S USA (Frank et a!. 2001 b) 
35T>C 112T Finland 2 
heterozygote with 
45G>C l15F UK 7 
SA 
59A>C H20P SA 
78insC Framashift, prenrature stop codon Finland 2000): 
INTRON2 
IVS2·2A;>C stop Finland 2000); 
EXOM! 
113G>C R38P France (Whalley et a!. 1999) 
119G>A G40E France (Whatley et al. 1999) 
157·16Ode1ATCT Frameshift, premature stop codon UK (Whatley et al. 1999): (Donnelly et at 2002) 
165insAG Frameshift, premature stop codon Germany (lam et al. 1997) 
17SC>T R59W SA Common, 
founder 
mulation 
Holland 5 (de RooiJ et al. 1997b) 
1S9-200insT Frameshift. prenrature stop codon France (Whatley et a!. 1999) 
202G>A G68R Italy (O'Amato at al. 2003) 
218T>C l73P UK. Italy et at 1999), (ei PleITO et al. 2003) 
IMlROM3 
IVS3-1G>C Splicing defect. deletion 01 axon 4 France (Whatley et al. 1999) 
EXOM4 
251T>G V84G UK (Whatley et at 
254T>C 185P France 2 (Whatley at al. 1999) 
306insC Frameshift;premature stop codon Italy (Patti at a!. 2003) 
317A>C H106P Argentina (De SiefvI et at 2000) 
















































Splicing defect USA 
Frameshift. premalure stop codon UK 2 
Frameshifl. premature stop codon UK 1 
W129U Italy 1 
E133X (nonsense mutation) Germany 1 
R138P SA 1 
F rameshift, premature stop codon Italy 1 
D143V France 1 
R152C France, Sweden 1 
Finland 
Frameshifl. premature stop codon UK 
L154P France 
Deletion of exon 5 and 20bp Finland 



















Frameshifl.. premature stop codon France 
L178V Argentina 
Framesl1ift. premature stop codon SA 
UK 
Frameshift. premature stop codan France 
Frameshift, premature stop codon UK 
Q189X (nonsense mutation) UK 
USIHoliand 
E191X (nonsense mutation) US I Germany 
L 198X (nonsense mutation) France 
Frameshift, premature stop codon Sweden 
A205V Sweden 
Deletion of exon 6 
Deletion of exan 7 
Not determined (but 

















(Frank el al. reported as 337+1G>A in text and 
333+1G>A in table 
(Whatley et at 1999) 
(Wha1ley et al. 1999) 
(D'Amato et al. 2003) 
(Frank et al. 1998b) 
(Comgall et al. 20oob), compound hetarozygota with R59W 
(O'Amato et al. 2003) 
(Whatley et at 1999) 
(Whatley et al. 1999); (Wiman et al. 2003) 
(Kauppinen etal. 1997);133;136 
(Whalley et al. 1999) 
(Wha1ley et al. 1999) 
(von und zu Fraunberg et al. 2001) 
(Whalley et at 1999) 
(Wiman et al. 2003) 
(~I~"'" al. 1998b); 
et at 1996), compound heterozygote with R59W 
(Whalleyet al. 1999) 
(de Rooij et at 1997b) 
(Frank et at 1997) 
(Frank et al. 2001a) 
~R~berts el al. ,~y:::~!:.'g" et at 1 S98d), compound 
(Whatley et al. 1999) 
(Whalley el al. 1999) 
(De Siervi et al. 2000) 
(Comgall et al. 1998), reported as 537deIAT 
(Whatley et al. 1999) 
(Whatley et al. 1999) 
el al. 1999) 
(Whatleyeta1.1999), reported as E189X 
(Frank el al. 2001 b) 
(Frank el a!. 2001 b) 
(Whalley et al. 1999) 
(Wiman et al. 2003) 
(Wiman et al. 2003) 
(Whalleyetal. 1999) 
(Whalley et a!. 1999) 











6571ns12 A219KANA UK 1 et al. 1998), compound heterozygote with IVS11-
857-658ins12 A219KASA UK 1 2001), 
heterozygotes with IVS11-1G>A 
672G>A W224X (nonsense mlrtation) France 2 (Whatley et at 1999) 
694G>C G232R France, Italy 2,1 et al. 1996);(WhaHey et at 1999);(D'Amato et al. 
695G>C G232R France 1 (Whatley et al. 1999) 
745-746insC Frameshlft, premature stop codon France 1 etal. 
al. 
745-746insG Frameshift, premature stop codon France 1 etal. 
745de1G Frameshift, premature stop codon France and UK 2 (WhaHey et al. 1999) 
759deIA Frameshift, premature stop Italy 1 (D'Amato et at 2003) 
759-76Ode1AG Frameshift, premature stop codon Japan 1 (Maeda et al. 2000), reported as 759delAG 
769deIG;nOT>A Frameshift, premature stop sodon SA 1 (Conigall et al. 2001) 
803G>A W268X (nonsense mlrtalion) UK 2 (Whalley et a!. 1999) 
INTRON7 
IVS7+2T>C Deletion of exon 7 UK 1 (Whatley et al. 1999) 
IVS7+1del18 Splicing defect, exon 7 deleted UK 1 (Roberts et al. 1998), compound heterozygote with G358R 
IVS7-9T>G Creation of an additional splice UK 1 (Whalley et al. 1999) 
results in 8bp added 
to 5' ofexon 8 
EXONS 
841-643deICAC H281del France 3 (Whatley et al. 1999) 
848T>A 1283N Italy 1 (D'Amato et al. 2003) 
849insT Frameshift, premature stop codon Holland 1 (de Rooij et at 1997b), reported as 1126+T 
845T>A V282D UK 2 (WhaHey et al.1999) 
851G>T 52841 Italy 1 (Patti et al. 2003) 
856delA Frameshift, premature stop codon France 1 (Whatley el al. 1999) 
868G>A V290M SA 1 (Conigall et al. 2001) 
868G>C V290l UK 1 (Whatley et af. 1999) 
915-916deITG Frameshift, premature stop codon US/Italy 1 (Frank al al. 2001 b) 
INTRONS 
None reported to 
date 
EXONS 
872T>C 1291P Holland 5 (de Rooij et at 1997b) 
884T>C 1295P UK 6 (Whalley et al. 1999) 
916-917deICT Frameshift, premature stop codon Sweden 1 (Wiman et al. 2003) 
INTRON9 
IVS9-1G>C Deletion of exon 10 UK 1 (Whatley et al. 1999) 
EXON10 
988G>C G330R Sweden 1 (Wiman et at 2003) 
998A>T H3331. Holland 1 (de Rooij el a!. 1997b), reported as within axon 9 
1004T>G V335G France 1 (Whatley et at 1999) 
1013C>G S338X (nonsense mutation) Italy 1 (D'Amato et at 2003) 
1043A>G Y348C SA 1 (Conigall et al. 2000a), compound heterozygote with R59W 
1048A>C D349A UK 1 (Roberts et at 1998), homozygote 










1 061 C>T P354L Italy et al. 2003). compound heterozygote wi1h 
1072G>A G358R UK 2 (Roberts et al. heterozygotes with G169E 
and IVS7+1de118 1998d) 
1043-1 044ins T Frameshift, premature stop codon Argentina 2 (De SieM et al. 2000). reported as 1320insT 
1 053-1 054insT Frameshift. premature stop codon UK (Whatley et at 1999) 
1081·1082insG Frameshift, premature stop codon UK (Whatley et al. 1999) 
1 082-1 083iilsC Frameshift. premature stop codon France 6 (Whatley et al. 1999) 
1083deIT Frameshift, premature stop codon France (Whatley et al. 1999) 
USA (Frank et al. 2001 b) 
1 083-1 084insG Frameshift. premature stop codon France (Whatley et at 1999) 
1090-1091 delAG Frameshift, premature stop codon UK (Whalley et al. 1999) 
1091insA Frameshift, premature stop codon USA (Frank et al. 2001 b) 
1093G>A V365M No details No details (Frank etal. 1997) 
INTRON10 
IVS10-1 G>T Deletion of exon 11 France (Whatley et al. 1999) 
IVS10+1G>A Aberrant splicing. premature slOp China (Lam et al. 2001) 
codon 
IVS10+2T>G Splicing defect Italy (D'Amato et al. 2003) 
EXON 11 
1106T>C predicted to be disease Denmark (Christiansen et al. 2001), reported as 1383T>C 
considering introduction of 
non-flexible proline 
1119G>A W373X France (Whatley et a!. 1999) 
1123C>T Q375X (nonsense mutation) Canada (Corrigall et al. 2001) 
1136C>Ains13 Frameshift, premature stop codon Holland (de Rooij et al. 1997b), reported as 1413C>A+13bp 
1144-1145de1GT Frameshift, premature stop codon American I (Frank et al. 2001 b) 
Indian 
1147-1148deIGT Frameshift, premature slOp codon France (Whalley et at 1999) 
1194-1198derrACAC Frameshift, premature stop codon Chile 4 {Frank etal. 2001a), reported as 1239derrACAC 
1203A>C L401F Finland (von und zu Fraunberg et al. 2001) 
INTRON 11 
IVS11-1T>G Namnal mRNA <90% UK et al. 1998), compound heterozygote wi1h 
IVS11-1G>A of axon 11 and UK al. 2001), compound heterozygota wi1h 
EXON 12 
1274-1275deIGT Frameshift, premature stop codon UK (Whatley et al. 1999) 
1281G>A W427X (nonsense mutation) UK (Whatley et al. 1999) 
1287deIA Frameshift, premature stop codon France 2 (Whatley et a!. 1999) 
1289insT Frameshift, premature stop codon Holland (de Rooij at al. 1997b), reported as 1566+ T 
INTRON12 
IVS12+1de1G Deletion of axon 12 France 2 (Whatley et a!. 1999) 
1VS12+1G>C Splicing defect USA, Italy (Frank etal. 2001 b), reported as 1290+1G>C 
IVS12+2T>G Splicing defect Sweden (Wiman et al. 2003) 
IVS12+2-3insT Splicing defect Sweden (Wiman et al. 2003) 
IVS12-2A>G Deletion of axon 13 UK (What/ey et a!. 1999) 
Turkey as 1292-2A>G in text and 











1292·1293de1AG Frameshift, pramature stop codon UK 2 (Whatley at al. 1999) 
1297G>C A433P UK 1 (Roberts et al. 1998), homozygote 
1299deIT Frameshift, premature stop codon Japan 1 (Maeda et at 2000) 
1303C>T Q435X UK 5 (Whatley et al. 1999) 
USA 1 (Frank et al. 2001 b) 
1320insT Frameshif!, prematura stop codon Argentina 2 (De Siervi et al. 2000) 
1330deIT Frameshift, premature stop codon Chile 1 (Frank et a!. 2001a) 
1330-31 delCT Frameshift, premature stop codon SWeden 1 (Wiman et al. 2003) 
1331T>C L444P UK 1 (Whatley et at 1999) 
1342G>A G448R Japan 2 (Maeda et al. 2000) 
1348T>C S450P UK I European 1 etal. 
etal. 
1357G>A G453R UK 1 (Whatley et al. 1999) 
1358G>T G453V UK 1 (Whatley et at 1999) 
1384-1385de1AG Frameshift, premature stop codon France 1 (Whatley et a!. 1999) 
INTRON 13 
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Axiovision software. Overlay images were created using Adobe Photoshop, 
v5. 
6.4 Results and Discussion 
6.4.1 Engineering of VP-causing mutations 
In wild-type human PPOX DNA an additional Hind"l restriction endonuclease 
cutting site was successfully engineered upstream of the stop codon and 
confirmed by direct sequencing as shown in Fig 6.1. (Prior to this engineering, 
the Hind III downstream of the stop codon of Fig 6.1 was a unique site.) 
Fig 6.1 
G AA G C TT A C A G C T G AAA G C TT G 
Partial sequence using a forward oligonucleotide of the PPOX carboxy terminal 
end indicating the incorporated Hind III restriction endonuclease sites to enable 
removal of the stop codon (TGA). Hind III sites are single underlined and the stop 
codon is doubly underlined. 
After removal of the stop codon, three VP-causing mutants H20P, R59Wand 
R168C were successfully engineered using site-directed mutagenesis and 
confirmed by direct sequencing (Figs 6.2 and 6.3). 











• Wild type C A G T T A Ce A ce T 


















G G G 









Wild type G T e T C T G ee G T G G A G T G G T 
Mutant 
Fig 6.2 
G T e T C T G e T G T G G A G T GG T 
Direct sequencing using forward oligonucleotide of respective fragments of 
engineered PPOX eDNA. In each case, the wild-type sequence is indicated 
above. 















6.3 the three mutants 


















1 2 3 4 5 6 
SSCP of the PCR product of fragment 1 to identify the H20P mutant. 
Lane 1, H20P +ve colony, lanes 2 & 4-6, H20P -ve colonies, lane 3, R59W 
(positive control). 
1 2 3 4 5 6 7 8 
500 bp ~ 
400 bp ~ 
100 bp ----. 
Ava I restriction analysis of the PCR product of fragment 1 to identify the R59W 
mutant. Lane 1, bp markers, lanes 2-5, wild-type (post-digestion), and lanes 6-8 









Bsa J1 restriction analysis of the 411 bp PCR product of fragment 2 to identify the 
R168C mutant. Lane 1, digested R168C positive clone, lane 2, Wild-type PPOX 
fragment 2. The sizes indicated on the left are based on a 25bp marker omitted from 
this figure due to it being adjacent to a number of irrelevant lanes. 










6.4.2 Engineering of PPOX-GFP fusion proteins 
Direct sequencing was performed in both wild-type PPOX and all 3 VP-
causing mutants to confirm in-frame ligation into the GFP expression vector 
as seen in figure 6.7. 
Fig 6.7 
T T CG A AGC T ~G CC G C TG AT G CC T CCGC 
Partial direct sequence using the forward oligonucleotide of the R59W-GFP 
fusion protein. The Hindlll site is underlined and the start site of the GFP 
vector is doubly underlined. The "\" indicates the PPOX-GFP ligation 
interface. 
6.4.3 Mitochondrial targeting of fusion proteins 
Wild-type PPOX-GFP : Predictably, the wild-type PPOX-GFP fusion protein 
targeted to the mitochondrion (Fig 6.BA1). For orientation and visualization, 
the cells are outlined in white with their nuclei encircled in red (Fig 6.8A1-3). 
Mitochondrial-specific targeting was confirmed by the co-localization of 
MitoTracker Red, a dye that accumulates and fluoresces red in the reduced 
environment of active mitochondria (Fig 6.8A 1-3). Intracellularly, the 
mitochondrial localization was very clear, presenting as punctate, "fluorescent 
oval or cigar-shaped tubes (depending on the orientation of the 
mitochondrion) characteristic of the specific localization in the OTe 
presequence positive control (Fig 6.8F). This was in contrast to the diffuse, 
cytosolic pattern exhibited by the EGFP vector (negative control) (Fig 6.8E). 












PPOX-GFP fusion proteins transfected into HepG2 cells visualized by fluorescent 
microscopy. A 1, Wild-type PPOX-GFP demonstrating intracellular mitochondrial 
= non-targeting 
localization. A2, MitoTracker red fluorescence. A3, Merged (green overlaid with red) image. 
Cells are outlined by dotted lines and the nuclei are circled in red. B, H20P-GFP fusion 
protein showing a diffuse cytosolic pattern of fluorescence. C, R59W-GFP fusion protein with 
the cells outlined by white dotted lines. D, R168C-GFP fusion protein. E, EGFP vector 
transfected alone acting as a negative control. F, OTC-GFP fusion protein used as a positive 
control of intracellular mitochondrial localization. All photographs were captured at 1000X 
magnification under oil and processed using Zeiss Axiovision software. Merged images 
were processed using Adobe Photoshop software. 

























































GIlJ'lAAIf\:PItARG- -ARVSWES DDHFGGKWTDR - RDGFLVEQGPDS FVAYRPA- - -
."I'-"" .......... 'I"LEAG- -ARVTVLEASGRVGGKL:'PGE- r AGVRVDLGAESMLARHPE---
QQRGVPY--VLLEAGDSFGGKVQSERTEDEFLVEKAADAFILGKPW---
RQAGDDATITLFEPADRLGGVLRTEH-IGGQPHDLGAEAFVLRRP---
Sequence alignment of the first 70 amino acid residues of PPOX from 18 
different organisms using the Jpred multiple sequence alignment program 
(www.expasy.ch). Top, human PPOX (H. sapiens). Seventeen PPOX 
sequences are numbered on the left. 1, Cichorium intybus (chicory); 2, 
Solanum tuberosum; 3, Nicotiana tabacum; 4, Drosophila melanogaster, 5, 
Bacillus subtilis; 6, Glycine max (soybean); 7, Chlamydia trachomatis; 8, 
Chlamydomonas reinhardtii; 9, Chlamydomonas pneumoniae; 10, 
Saccharomyces cerevisiae; 11, Solanum tuberosum; 12, Aquffex aeolicus; 
13, Myxococcus xanthus; 14, Mycobacterium leprae; 15, Propionibacterium 
freudenreichii; 16, Dynococcus radioduran; 17, Mycobacterium tuberculosis. 
Yellow boxed area, highly conserved dinucleotide-binding motif. Grey boxed 
area, His20 residue. The Arg59 residue is marked by a red asterisk. M. 
xanthus (13*) is the only other organism in which His20 is conserved. 
Interestingly, an unusually high frequency of mutations in the PPOX gene 
associated with the replacement of wild-type amino acids by proline has been 
reported in UK VP patients (Whatley et al. 1999b). Thirty five percent of their 
missense mutations represent a substitution by proline. The majority are 
leucine to proline substitutions. Other mutations reported include a serine to 
proline mutation at codon 450 (S450P) (Frank et al. 1998) and an arginine to 
proline at codon 138 (R138P) (Corrigall et al. 2000). Proline is known to 
decrease protein flexibility (Tian et al. 1998) as it is bonded covalently to the 
nitrogen atom of the peptide backbone and thus has no amide hydrogen for 
use as a donor in hydrogen bonding or resonance stabilization of the peptide 
bond of which it is part. Moreover, the cyclic five-membered proline ring 
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o MGRTVWLGGGISGLAASY.!:::!LSRA _ PPOX24-GFP 
MGRTWVLGGGISGLAASY.t! _ PPOX20-GFP 
MGRTWVLGGGI _ PPOX12-GFP 
MGRTWVLGGGISG _ PPOX14-GFP 
MGRTWVLGGGISGL _ PPOX15-GFP 
MGBTVWLGGGISGLA _ PPOX16-GFP 
MGRTVWLGGGISGLAA_ PPOX17-GFP 
M!:LGGGISGLAA _ PPOX17-GFP 
M - LGGGISGLAA_ PPOX17-GFP 
M S LGGGISGLAA _ PPOX17-GFP 






@] MSYHLSRAP .......... TEPNSS _ PPOU1-17-GFP 
Schematic presentation of PPOX-GFP constructs engineered. A, The 
constructs were tested in the sequence as listed (see text). 
Positively-charged residues are underlined. 8, 17-residue N-terminal 
mitochondrial targeting sequence constructs. Arg3 (wild-type) was 
altered to the residues as indicated in colour. C, 20-residue 
constructs with His20 (wild-type) altered to the residues indicated in 
colour. D, PPOX-GFP construct with a deletion (~) of residues 1-17 
to identify potential downstream/internal targeting signals. Colour 
code for sections Band C : Red, negatively charged residue; blue, 
positively charged residues; brown, neutral residues; black, 
hydrophobic residues. 
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L15 G14 S13 112 G11 
A T T CG A AG C T ~ C A AG CC G C T G A T G CC 
IfMIIAMrMiltMM 
H2° y19 S18 A17 A16 




200 bp -------. .--197bp 
1 2Sbp-------. .--12Sbp 
7 SbP-------. 
72bp 
SOb P -------. 
2Sbp -------. 
Partial reverse direct sequencing of PPOX15-GFP (A) and PP0X20-GFP (8) and 
restriction enzyme analysis on a 6% acrylamide gel (C) to confirm in-frame ligation. 
Amino acid residues are indicated above the sequence according to their genetiC 
codes. The code is located above the central nucleotide of the codon and its 
numbered position in the PPOX sequence is superscripted. The Hind III site is 
underlined. C, PP0X24-GFP PCR fragment (197bp) using oligonucleotides flanking 
the PPOX-GFP interface, followed by digestion with 8g1 II/Hind III. The 25bp marker is 
shown on the left. Lane 1, undigested peR fragment, lane 2, digested fragment 
(respective sizes are shown on the right). 
Problems such as low ligation efficiency and incorrectly-sized ligated products 
were initially encountered when gel-purified GFP expression vector and 
PPOX peR fragments were ligated. These may have resulted from remaining 
salts and solvents within the agarose gels. The problem was solved by 
adopting a "shotgun" ligation approach in which unpurified PPOX fragments 
and GFP vector were digested and immediately ligated in a ratio of PPOX 
fragment: GFP :: 7 : 1. 






















,/ = targeting 
X = non-targeting 
Series of PPOX-GFP constructs and controls transfected into HepG2 cells. 
A, PP0X24-GFP; B, PP0X20-GFP; C, PPOX12-GFP; D, PPOX14-GFP; E, PPOX15-GFP; 
F, PPOX16-GFP; G, PPOX17-GFP, H, OTC-GFP fusion protein (positive control of 
intracellular mitochondrial localization); I, EGFP vector transfected alone (negative 
control). All photographs were captured at 1000X magnification under oil and processed 
using Zeiss Axiovision software. 





























Predicted a-helical wheel diagram of residues 1-17 of human PPOX. Hydrophobic, 
neutral and positively charged residues are indicated in black, brown and blue, 
respectively. Predictive software used was shareware found at : 
(2-[0 " ,U co..,:: , 
A I GFP-PPOX17 G4 __ MGRTVWLGGGISGLAA 
B 
GFP-PPOX 17 construct transfected into HepG2 celis illustrating that attachment of 
PPOX17 to the carboxy terminus of GFP did not facilitate mitochondrial targeting. 










B. Effect of net positive charge on the N-terminal targeting signal 
Fig 7.7 
Engineering of GFP constructs 
A I MGETVWLGGGISGLAA-IC1j* PPOX17/R3E-GFP 
v T E G M 
C A e G A e Ie A e IG G T Ie -:;-e f e c lc A ~ G C T A 
8 MGKTVWLGGGISGLAA-WC1iil PPOX17/R3K-GFP 
V T K G M 
e A C G A c lc A CIGG T ic ~IG cc~ A T~ e T A 
J&~ANvf\NwfI\JI\ 
c MGSTVWLGGGISGLAA--4C!,. PPOX17/R3S-GFP 
V T ~ G M 
.G A e I C A c IGG T IG C T IG C C I C A ~ G C T 
~!\rAr&rNvi1\d 
Schematic diagram showing constructs and partial direct reverse sequences 
of PPOX17-GFP. Arg3 was successfully altered to : A, glutamic acid (R3E); 
B, lysine (R3K); and C, serine (R3S). Altered residues are in bold and 
underlined. Amino acid residues are indicated above the direct sequence. 










































Series of PPOX-GFP constructs to examine the effect of changing the net charge of 
the mitochondrial targeting sequence. A, PPOX17/R3E-GFP; B, PPOX17/R3K-GFP; 
C, PPOX 17/R3S-GFP. 
TT C G AA G C T T G T GG T AA C T GG C GG CC 
A~
A A T T C G AA G C TT G C T G T A A C TG G C G G C 
B ~~NL\rr~M&M~ 
. AA G C T T G G C G T A AC T G G C G G C C AA G C C 
D 
AA TT C G AA G C T T C TT G T AA C T GG C GG 
fv'Vlf\AfIIW\M!J\" f'!IMMflAi 
A A G C T T e T C G T A A CT G G C GG C C A AG C C 
E~d 
F~ 
Partial direct reverse sequencing of engineered H20 constructs A, PP0X20-GFP 
(wild-type); B, PP0X20/H20S-GFP; C, PP0X20/H20A-GFP; D, PP0X20/H20K-GFP; 
E, PP0X20/H20E; F, PP0X20/H20G. In all cases the changed residues are underlined. 
























,/ = targeting 
)( = non-targeting 
Series of PPOX-GFP constructs mutated at the H20 position. A. PP0X20/H20S-GFP; 
B, PP0X20/H20A-GFP; C, PP0X20/H20K-GFP; 0, PP0X20/H20E-GFP; E, PP0X20/H20G-
GFP; F, PP0X20/H20P-GFP; G, OTC-GFP fusion protein (positive control). 













































CGAA GCT T fT ~ Ar~ TIG ~T~ ~GIT i CITG 
B~
Confirmation of positive PPOM1-17-GFP colonies. A, Rapid screening 
technique on a 0.8% agarose gel. Lanes 1-3 and 5-9, positive colonies, lane 4, GFP 
vector. B, partial direct sequencing using a reverse oligonucleotide. The Hind"l site is 
underlined. The asterisk (*) indicates the stop codon (TGA) converted to serine (TCA) 
via PCR-based mutagenesis to allow in-frame translation. The amino acid residues 
are shown above the codons. 
PPOXA1-17-GFP MSYHLSRA ............. TEPNSS --AiM 
Transfection of the PPOM1-17-GFP construct exhibiting punctate fluorescent ovals 
indicative of intracellular mitochondrial localization. 










































































A summary of relevant structural and functional information on human PPOX. 
Information obtained from this study is indicated in blue. 
Secondary structure/Function and References 
comments 
p-sheet - only p-sheets relevant to this (Von Und Zu Fraunberg et al. 2003) 
study are listed 
a-helical hydrophobic motif (LXXXIXXL) (Von Und Zu Fraunberg et al. 2003) 
- the isoleucine (112) and leucine (L 15) 
residues are highly conserved across 
species 
Tetrapeptide helical breakers - known to This study (see text) 
exist at the start and end of helices 
Predicted cleavage site - although this This study (see text) 
could not exist in human PPOX as the 
FAD binding motif would be lost with 
subsequent loss of functionality. Only A. 
thaliana (Narita et al. 1996) and spinach 
PPOX (Watanabe et al. 2001) contain 
cleavable N-terminal targeting signals. 
a-helix - based on structural biology (Von Und Zu Fraunberg et al. 2003) 
principles, this would start at 112 rather This study (see text) 
than G11 (see text) Morgan et aI., personal communication 
Inter-helical fold Morgan et aI., personal communication 
N-terminal mitochondrial targeting signal This study (see text) 
(Von Und Zu Fraunberg et al. 2003) 
Region containing putative internal This study (see text) 
mitochondrial targeting signal(s) (Von Und Zu Fraunberg et al. 2003) 
Morgan et al.. personal communication 
Hydrophobic domains (Von Und Zu Fraunberg et al. 2003) 
Putative membrane-anchoring domain (Arnould and Camadro 1998; Arnould 
et al. 1999) 
FAD-binding domain (GXGXXG) - (Dailey and Dailey 1998) 
highly conserved among a large number 
of FAD binding proteins 
































































































_ Hydrophobic domains 
G Hydrophobic negative 
domains 
_ Putative internal signals 
_ FAD binding site 
IL\~I Membrane potential 
Fig 8.1 Proposed mechanism of PPOX targeting, A-J, see text. 
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Experimental human PPOX constructs, the oligonucleotides used to engineer 
them, and their associated bp sizes. Where amino acids have been changed 
from wild-type, they are indicated in blue. The incorporated 8g1 II restriction 
endonuclease site is bolded and under1ined. The Hind III site is bolded and 
twice under1ined. 
Oligonucleotide SequenceJs Fragment Size (bp) 
(5'-3'),31-mer 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 65 bp 
R : AAG AAA CAA Gel lGA TGC CTC CGC CCA GCA C 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 71 bp 
R : AAG AAA CAA Gel lGC CGC TGA TGC CTC CGC C 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 74 bp 
R : AAG AAA CAA Gel lCA AGC CGC TGA TGC CTC C 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 77 bp 
R : AAG AAA CAA Gel lGG CCA AGC CGC TGA TGC C 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 80 bp 
R : AAG AAA CAA Gel lGG CGG CCA AGC CGC TGA T 
F : GTT TCT TAG ATC TAG CAT GGG CAG CAC CGT G 80 bp 
R : AAG AAA CAA Gel lGG CGG CCA AGC CGC TGA T 
F : GTT TCT TAG ATC TAG CAT GGG CGA GAC CGT G 80 bp 
R : AAG AAA CAA Gel lGG CGG CCA AGC CGC TGA T 
F : GTT TCT TAG ATC TAG CAT GGG CAA GAC CGT G 80 bp 
R : AAG AAA CAA Gel lGG CGG CCA AGC CGC TGA T 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 89 bp 
R : AAG AAA CAA Gel lGT GGT AAC TGG CGG CCA A 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 89bp 
R : AAG AAA CAA Gel l GG GGT AAC TGG CGG CCA A 
F: GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 89 bp 
R : AAG AAA CAA..GC.I..IGC TGT AAC TGG CGG CCA A 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 89bp 
R : AAG AAA CAA Gel I GG CGT AAC TGG CGG CCA A 
F: GTTTCT TAG ATC TAG CAT GGG CCG GAC CGT G 89 bp 
R : AAG AAA CAA Gel I CT TGT AAC TGG CGG CCA A 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 89 bp 
R : AAG AAA CAA GCI I CT CGT AAC TGG CGG CCA A 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 89 bp 
R : AAG AAA CAA Gel I GC CGT AAC TGG CGG CCA A 
F : GTT TCT TAG ATC TAG CAT GGG CCG GAC CGT G 101 bp 
R : AAG AAA CAA Gel IGG CCC GGC TCA GGT GGT A 
F : GTG TAG ATC TAT GAG TTA CCA CCT GAG CCG G 101 bp 
R : ACA CAA GCI ITG AGC TGT TAG GTT CTG TGC C 
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MitoProt calculates the N-terminal protein region that can support a Mitochondrial 
Targeting Sequence and the cleavage site. The official site is found at : 
http://websvr.mips.biochem.mpg.de/proVmedgen/mitop/ 
A complete description of the prediction methodology is available in: M. G. Claros, P. 
Vincens. Computational method to predict mitochondrially imported proteins and their 





PredictProtein is a secondary structure predictor for an input amino acid sequence. It 
compares the input sequence with a large database (PROSITE) and the results are 
output as predictions of multiple sequence alignments (PSI-BLAST and MAXHOM), 
secondary protein structural information ie. alpha helices and beta sheet content 
(PROF) and prediction of protein globularity (GLOBE). The official website for 
PredictProtein is : 
http://cubic.bioc.columbia.edu 
A complete description of the method can be found in : Rost, B. (1996) Methods in 
Enzymology, 266: 525-539. 
10.3 a.-HelixWheel prediction 
HelixWheel is shareware that analyzes the input sequence for its ability to form an 0.-
helix and then plots this on a wheel diagram indicating hydrophobic, hydrophilic, 
positive and negative-charged residues using a colour scheme. The predictive 
software used can be found at : 
(http://www.site.uottawa.caI-turcotte/resources/HelixWheel). 










11. Amino acid structure classification 
NEUTRAL AND HYDROPHOBIC 
AlanIne (Ala A) Vaine (Val V) 
BASIC ACIDIC 










12. PPOX cDNA Sequence 
Table 10. cDNA sequence for human PPOX (Nishimura, K. et al. Cloning of a human 
cDNA for protoporphyrinogen oxidase by complementation in vivo of a hemG 
mutant of E. coli. J. BioI. Chem. 270 (14), 8076-8080 (1995), Accesion 
#038537). Oligonucleotide sets were designed to PCR the entire gene in four 
fragments. The forward oligonucleotides are underlined, and the reverse 
oligonucleotides are double-underlined. The mutations of interest in this study 
are colour-coded in the right-hand column. The start (ATG) and termination 
(TGA) codons are boxed in red. 
GAATTCGGGGGGAGAACAGAGTGGACGGAGAGTAGGAGAG 
ACCGAAAAGG CTGGGGGTGG GAGT AGCGGA TITGAAGCAC 
TTGTTGGCCT ACAGAGGTGTGGCAAGCAGA GCACCTCAGA 
ACTCAGGCGTACTGCCCGCCGCCCGAGCCCTGCGAGGGCC 
GATAGCGAGGGTGTGGCCCTTATCTGCACCCAGCAGAGCG 
CCGGCGGGGT ACGGTCTT AG GACCTCGATC TCCTTCTCCC 
TCA TITTCTC TCATCCCT AC CT A TTGTGGG TITCC~ 
GGCCGGACCGTGGTCGTGCTGGGCGGAGGCATCAGCGGCT 
TGGCCGCCAG TT ACC\M::CTG AGCCGGGCCC CCTGCCCCCC 
TAAGGTGGTC CTAGTGGAGA GCAGTGAGCGTCTGGGAGGC 
TGGATTCGCTCCGTTCGAGGCCCTAATGGTGCTATCTITG 
AGCTTGGACC T~IGGGGAA IT AGGCCAGCGG GAGCCCTAGG 
GGCCCGGACC TTGCTCCTGG TITCTGAGCT TGGCTTGGAT 
TCAGAAGTGCTGCCTGTCCGGGGAGACCACCCAGCTGCCC 
AGAACAGGTT CCTCT ACGTG GGCGGTGCCC TGCATGCCCT 
ACCCACTGGCCTCAGGGGGCTACTCCGCCCTTCACCCCCC 
TTCTCCAAAC CTCTGTITTG GGCTGGGCTG AGGGAGCTGA 
CCAAGCCCCGGGGCAAAGAGCCTGATGAGACTGTGCACAG 
TTITGCCCAG CGCCGCCTTG GACCTGAGGT GGCGIC..ICI.A 
GCCATGGACA GTCT CTG@ TGGAGTGTIT GCAGGCAACA 
GCCGTGAGCT CAGCATCAGG TCCTGCTITC CCAGTCTCTT 
CCAAGCTGAG CAAACCCATC GTTCCAT A TT ACTGGGCCTG 
TTGCTGGGGG CAGGGCGGAC CCCACAGCCA GACTCAGCAC 
TCATTCGCCA GGCCTTGGCT GAGCGCTGGA GCCAGTGGTC 
ACTTCGTGGA GGTCT AGAGA TGIT..GCCTCA GGC.cCTTGAA 
ACCCACCTGA CTAGT AGGGG GGTCAGTGTT CTCAGAGGCC 
AGCCGGTCTGTGGGCTCAGCCTCCAGGCAGAAGGGCGCTG 

















(TABLE 10 CONTD .... ) 
GAAGGT ATCT CT AAGGGACA GCAGTCTGGA GGCTGACCAC 
GTT A TT AGTG CCATTCCAGC TTCAGTGCTC AGTGAGCTGC 
TCCCTGCTGA GGCTGCCCCT CTGGCTCGTG CCCTGAGTGC 
CATCACTGCA GTGTCTGT AG CTGTGGTGAA TCTGCAGT AC 
CAAGGAGCCC ATCTGCCTGT CCAGGGA TIT GGACA TITGG 
TGCCATCTTC AGAAGATCCA GGAGTCCTGG GAA TCGTGT A 
TGACTCAGTT GCIITCCCTG AGCAGGACGG GAGCCCCCCT 
GGCCTCAGAGTGACTGTGATGCTGGGAGGTTCCTGGTTAC 
AGACACTGGAGGCTAGTGGCTGTGTCTTATCTCAGGAGCT 
GTITCAACAG CGGGCCCAGG AAGCAGCTGC T ACACAATT A 
GGACTGAAGG AGATGCCGAG CCACTGCTTG GTCCATCT AC 
ACAAGAACTG CA TTCCCCAG TAT ACACT AG GTCACTGGCA 
AAAACT AGAG TCAGCT AGGC AA TTCCTGAC TGCTCACAGG 
TTGCCCCTGA CTCTGGCTGG AGCCTCCTAT GAGGGAGrrG 
CTGTTAATGA CTGTATAGAG AGTGGGCGCC AGGCAGCAGT 
CAGTGTCCTGGGCACAGAACCTAACA~CCCCAACT 
CTCA TTCATG AAAA T AAAAA TTGCTGGAGC TCCCGAA TCC 
CGAATTC 
Table 11 Engineered PPOX mutants with their corresponding fragment and size. 
Mutant Corresponding Fragment Size (bp) 
H20P 1 533 
R59W 1 533 
R168C 2 411 
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